MedTrace Logo

COVID-19 Primary Care Platform for Early Treatment and Recovery (COPPER) Study

NCT04746430 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2021-05-11

No results posted yet for this study

Summary

The COVID-19 coronavirus has led to a global pandemic of respiratory diseases with an increase in hospitalization and death risk. To keep COVID-19 manageable for healthcare, early treatment is urgently needed to avoid hospitalization. Dexamethasone can dampen the exaggerated cytokine response to COVID-19 and is a promising agent for preventing disease aggravation, hospitalization and death. However, the evidence on the effectiveness, safety and cost-effectiveness of dexamethasone treatment in primary care is inconclusive.

Conditions

  • Covid19
  • Corona Virus Infection

Interventions

DRUG

Dexamethasone

6 mg dexamethasone prescribed during ten days and as a precaution combined with electronic monitoring of saturation and other signs and symptoms

Sponsors & Collaborators

  • Huisartsenzorg Drenthe

    collaborator UNKNOWN

  • General Practitioners Research Institute

    lead NETWORK

Principal Investigators

  • Janwillem Kocks, Prof · General Practitioners Research Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-16
Primary Completion
2021-04-23
Completion
2021-04-23

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04746430 on ClinicalTrials.gov